Novo Nordisk, a leading pharmaceutical company, has announced its decision to maintain availability of its popular insulin brand, Mixtard, in vial form in India, while discontinuing Penfill cartridges. This move comes amid apprehensions regarding the cessation of commonly used insulin products. The company’s strategy is geared towards streamlining its insulin offerings to cater to the rising needs of patients and guarantee a steady medication supply, with a focus on more advanced treatments.